drugset / Trial / NCT07118696
Evaluating a Shorter, Rifampicin-Based Treatment for People With Less Severe Tuberculosis Disease
Phase 3
Not yet recruiting
1000 enrolled
Hamilton Health Sciences Corporation
McMaster University · collabSt George's, University of London · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease severity.
Timeline
- Start
- 2026-02-01
- Primary completion
- 2029-01-31
- Completion
- 2030-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifampin | Small molecule | 600 mg | — |